Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Update

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 5,460,000 shares, an increase of 31.6% from the February 13th total of 4,150,000 shares. Currently, 6.9% of the company’s stock are short sold. Based on an average daily volume of 772,500 shares, the short-interest ratio is presently 7.1 days.

Analyst Ratings Changes

CNTA has been the subject of several analyst reports. TD Cowen began coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Morgan Stanley reissued an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $26.00.

Insider Buying and Selling

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the sale, the insider now owns 183,266 shares of the company’s stock, valued at $3,122,852.64. The trade was a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the transaction, the general counsel now directly owns 118,265 shares of the company’s stock, valued at approximately $1,808,271.85. This trade represents a 4.83 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 247,168 shares of company stock valued at $4,138,928. Company insiders own 11.59% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter valued at $31,000. GAMMA Investing LLC raised its position in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the period. Barclays PLC raised its position in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $162,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $171,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $16.51 on Wednesday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average price is $16.45 and its two-hundred day moving average price is $16.36. The company has a market cap of $2.18 billion, a PE ratio of -10.79 and a beta of 1.54. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.